Eli Lilly and (LLY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $8.38
- Estimate
- $6.58
- Surprise
- +27.3%
- Revenue (period 2026-06-30)
- $22.97B
- Score at report (before → after)
- 6.4 → 6.6/10
Revenue source: xbrl.
How the report landed
Eli Lilly and (LLY) beat the $6.58 estimate with diluted EPS of $8.38 — a large 27.3% upside surprise. TrendMatrix's engine moved from Hold (6.4/10) to Buy (Wait) at 6.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates LLY Sell at 6.3/10.
4 of the last 4 quarters beat the estimate; this quarter's +27.3% surprise compares with a +20.4% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- Strong earnings beat streak (4/4)
- High-quality business
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (3.6% away)
- Leverage penalty (D/E 1.6): -1.0
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $1245.63
- Price target
- $1266.80
- Stop
- $1158.51
- Upside to target
- +1.7%
The stock trades at 42.2× trailing but 26.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-08-24 — shown for context, not personalized investment advice.
LLY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $1119.01B
- P/E (fwd)
- 26.6
- P/E (ttm)
- 42.2
- 52-week range
- $694.23–$1292.65
- Off 52-week high
- 3.6%
- RSI (14)
- 69
- Volume vs avg
- 0.10×
- Score today
- 6.3/10